Combined Anti-Cancer Effects of Platycodin D and Sorafenib on Androgen-Independent and PTEN-Deficient Prostate Cancer

Zongliang Lu,Wei Song,Yaowen Zhang,Changpeng Wu,Mingxing Zhu,He Wang,Na Li,Yong Zhou,Hongxia Xu
DOI: https://doi.org/10.3389/fonc.2021.648985
IF: 4.7
2021-05-07
Frontiers in Oncology
Abstract:Castration-resistant (androgen-independent) and PTEN-deficient prostate cancer is a challenge in clinical practice. Sorafenib has been recommended for the treatment of this type of cancer, but is associated with several adverse effects. Platycodin D (PD) is a triterpene saponin with demonstrated anti-cancer effects and a good safety profile. Previous studies have indicated that PC3 cells (PTEN -/-, AR -/-) are sensitive to PD, suggesting that it may also be a useful treatment for castration-resistance prostate cancer. We herein investigated the effects of combining PD with sorafenib to treat PTEN-deficient prostate cancer cells. Our data show that PD promotes sorafenib-induced apoptosis and cell cycle arrest in PC3 cells. Of interest, PD only promoted the anti-cancer effects of sorafenib in Akt-positive and PTEN-negative prostate cancer cells. Mechanistic studies revealed that PD promoted p-Akt ubiquitination by increasing the p-Akt level. PD also increased the protein and mRNA expression of FOXO3a, the downstream target of Akt. Meanwhile, PD promoted the activity of FOXO3a and increased the protein expression of Fasl, Bim and TRAIL. Interestingly, when FOXO3a expression was inhibited, the antitumor effects of both PD and sorafenib were individually inhibited, and the more potent effects of the combination treatment were inhibited. Thus, the combination of PD and sorafenib may exert potent anti-cancer effects specifically via FOXO3a. The use of Akt inhibitors or FOXO3a agonists, such as PD, may represent a promising approach for the treatment of androgen-independent and PTEN-deficient prostate cancer.
oncology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is how to improve the anti - cancer effect by the combined use of Platycodin D (PD) and Sorafenib in the treatment of castration - resistant (androgen - independent) and PTEN - deficient prostate cancer. This type of cancer is a challenge in clinical practice. Although Sorafenib is recommended for the treatment of this type of cancer, it is accompanied by several side effects. PD is a triterpenoid saponin with anti - cancer effect and good safety. Previous studies have shown that PC3 cells (PTEN - / AR - ) are sensitive to PD, suggesting that PD may also be an effective drug for the treatment of castration - resistant prostate cancer. Therefore, the researchers explored the effect of the combination of PD and Sorafenib on PTEN - deficient prostate cancer cells. Specifically, the paper experimentally verified that PD can promote Sorafenib - induced apoptosis and cell cycle arrest, and this promoting effect was only observed in Akt - positive and PTEN - negative prostate cancer cells. Mechanism studies have shown that PD promotes p - Akt ubiquitination by increasing the p - Akt level, and at the same time increases the protein and mRNA expression of FOXO3a. PD also promotes the activity of FOXO3a and the protein expression of its downstream targets Fasl, Bim and TRAIL. When FOXO3a expression is inhibited, the anti - tumor effects of PD alone, Sorafenib alone, or the combination of the two will be weakened. Therefore, the combination of PD and Sorafenib may play a powerful anti - cancer role through the FOXO3a pathway. Using an Akt inhibitor or a FOXO3a agonist such as PD may be a promising method for the treatment of androgen - independent and PTEN - deficient prostate cancer.